Presentation is loading. Please wait.

Presentation is loading. Please wait.

DEFINITIVE AR - Acute Outcomes -

Similar presentations

Presentation on theme: "DEFINITIVE AR - Acute Outcomes -"— Presentation transcript:

1 DEFINITIVE AR - Acute Outcomes -
Directional AthErectomy Followed by a PaclItaxel-Coated BallooN to InhibiT RestenosIs and maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment Prof. Thomas Zeller, M.D. Universitaets-Herzzentrum Freiburg - Bad Krozingen Bad Krozingen, Germany

2 Contributors Co-Sponsors: Covidien and Bayer HealthCare (formerly MEDRAD) Principal Investigators: Prof. Thomas Zeller, MD & Prof. Gunnar Tepe, MD Angiographic Core Lab: SynvaCor, Springfield, IL Vascular Ultrasound Core Lab: Vascore, Boston, MA Sites: Universitaets-Herzzentrum Freiburg - Bad Krozingen (Bad Krozingen) Klinikum Rosenheim, Institut für Diagnostische und Interventionelle Radiologie Medical Care Center Prof. Mathey, Prof. Schofer, Hamburg Vascular Centre Berlin, Ev. Hospital Königin Elisabeth Herzberge gGmbH Heart Center Leipzig St. Franziskus-Hospital Münster Imelda Hospital Bonheiden Angiomed Krakow Universitäts-Spital Zürich, Klinik für Angiologie Medizinische Universitätsklinik III SC A

3 Study Design DAART* DCB
Purpose: Pilot study designed to assess and estimate the effect of treating a vessel with directional atherectomy + DCB (DAART) compared to treatment with DCB alone General and Angiographic Criteria Assessment Lesion severely calcified? Guidewire passage, enrollment & Randomization DAART* (N = 48) DCB (N = 54) Guidewire Passage & Enrollment (N=19) No Yes Yes Severe Calcification: Dense circumferential calcification and calcification extending more than five (5) continuous centimeters of length prior to contrast injection or digital subtraction angiography There was 6 month lag in ca++ arm due to prolonged enrollment period. Acute results from the ca++ arm will be presented soon. The sample size difference between groups is attributed to the blocked randomized trial design. Registry arm for severely calcified lesions created to limit bail-out stenting (and therefore variables) in randomized arm. * Directional Atherectomy + Anti-Restenotic Therapy SC A

4 Devices Bayer HealthCare’s Covidien’s Peripheral
SilverHawk ™ & TurboHawk™ peripheral plaque excision systems Bayer HealthCare’s Peripheral Paclitaxel-coated angioplasty catheter with Paccocath® Technology SC A

5 Study Design Study Design and Oversight Primary Endpoint
Prospective, randomized (DAART vs. DCB alone) 121 patients enrolled at 10 centers in Europe CEC, DSMB, and Steering Committee oversight Angiographic and Duplex Core Laboratory Analyses Primary Endpoint Percent Stenosis at 1 Year SC A

6 Study Design Key Inclusion Criteria Key Exclusion Criteria
RCC 2-4 Target lesion 7-15 cm in length RVD 4-7 mm Baseline stenosis ≥ 70% Key Exclusion Criteria In-stent restenosis Aneurysmal target vessel 2 or more lesions that require treatment in the target limb Follow-up assessments Pre-discharge, 30 days, 6 months, and 1 year post-procedure SC A

7 Baseline Demographics
DAART (N= 48) DCB (N = 54) P Value* Age 70.1 ± 9.7 69.0 ± 8.2 0.4383 Male 64.6% 68.5% 0.6807 History and Risk Factors Angina 4.2% 9.3% 0.4425 Diabetes 27.1% 35.2% 0.4014 Hypertension 87.5% 81.5% 0.4300 Hyperlipidemia 70.8% 0.8323 Renal Insufficiency 12.5% 14.8% 0.7807 Current/Previous Smoker 50.0% 63.0% 0.3076 Rutherford Clinical Category 0.9096 2 24.0% 3 74.1% 4 2.1% 1.9% *No significant differences between groups SC A

8 Baseline Lesion Characteristics Per Core Lab Assessment
DAART (N= 48) DCB (N = 54) P Value* Lesion Length (cm) 10.6 9.7 0.3034 Diameter Stenosis 82% 85% 0.3468 Reference vessel diameter (mm) 4.9 0.4794 Minimum lumen diameter (mm) 1.0 0.8 0.3372 Calcification 70.8% 74.1% 0.4758 *No significant differences between groups SC A

9 Technical Success Defined as ≤ 30% residual stenosis following the protocol-defined treatment at the target lesion as determined by the Angiographic Core Laboratory. DAART DCB P Value Technical Success 89.6% 64.2% 0.004 SC A

10 Minimum Lumen Diameters
DAART resulted in a significantly larger minimum lumen diameter (MLD) following the protocol-defined treatment (4.27 mm vs mm, P = 0.045) P = 0.045 MLD = 4.27 mm MLD = 3.78 mm Min. Lumen Diameter (mm) This slide shows the mean MLD at baseline and following each step of the protocol-defined procedure. DAART Arm: 8 lesions were pre-dialated DCB arm: 40 lesions were pre-dialated SC A

11 Adjunctive Therapy (Post protocol-defined treatment)
DAART (N= 48) DCB (N = 54) P Value Adjunctive Therapy PTA (post-dil) 6.3% (3/48) 33.3% (18/54) 0.0011 Bail-out Stent 3.7% (2/54) 0.4968 The bail out stenting rate in this trial is considerably lower than the DCB studies published to date Significantly higher rate of PTA following treatment with DCB in DCB arm SC A

12 Residual Stenosis Residual diameter stenosis was significantly lower in the DAART arm P = P = SC A

13 Periprocedural Complications (Per CEC)
DAART (N= 48) DCB (N = 54) p-value Distal Embolization 6% (3/48) 0/54 0.101 No Intervention 1 Surgical Intervention Endovascular Intervention 2 Dissection (flow-limiting, Grade C/D) 2% (1/48) 19% (10/54) 0.009 6 4 Perforation 4% (2/48) 0.219 SC A

14 Functional Outcomes Significant improvement in ABI & WIQ scores at 30 days in both cohorts Mean ABI at Baseline and 30 Days Percent of patients with Improvement in WIQ Scores at 30 days P < P < No significant differences between groups No significant differences between groups at baseline or at 30- days Baseline 30 days Baseline 30 days SC A

15 Conclusions Acute results of DAART treatment show:
Significantly higher technical success rate (DAART 89.6% vs. DCB 64.2%, P=0.004) Acceptable periprocedural complications Significantly lower dissection rate (DAART 2% vs. DCB 19%, P = 0.009) Long-term data to determine the durability of DAART vs. DCB are necessary and forthcoming SC A

Download ppt "DEFINITIVE AR - Acute Outcomes -"

Similar presentations

Ads by Google